简介
Paolo A. Ascierto obtained his medical degree from the University of Naples, Italy, the institution where he subsequently earned his Board Certification in Oncology. He went on to serve consecutive positions at the National Tumor Institute “Fondazione G. Pascale”, in Naples, as a postdoctoral fellow and then as Vice Director of the Department of Clinical Immunology. Professor Ascierto is currently Professor of Oncology at the University of Napoli "Ferderico II" and Director of the Department of Skin Cancers, Cancer Immunotherapy and Development Therapeutics at Istituto Nazionale Tumori IRCCS "Fondazione Pascale", Napoli, Italy. He is an active Scientific Reviewer for several international journals, including, NEJM, JCO, Lancet Oncology, and Clinical Cancer Research, as well as being Associate Editor of Annals of Oncology for Onco-Immunology, Deputy Editor and Chief Section Editor for Combination Strategies section of Journal of Translational Medicine, Section Editor of Journal of ImmunoTherapy of Cancer, and member of the Editorial Board of ESMO Open. As a result of Professor Ascierto’s experience and expertise, he has been a valued invited speaker at more than 600 national and international meetings. Furthermore, he maintains active memberships in several international medical societies. He was member of the Steering Committee of Society of Melanoma Research (SMR) 2016-2022, member of the board of Cancer Development Drug Forum (CDDF) 2017-2020, member of Board of Directors of Society of Immuno Therapy of Cancer (SITC) 2018-2021, as well as President of the Fondazione Melanoma Onlus since 2010, and President of Campania Society of ImmunoTherapy of Cancer (SCITO) since 2013. Professor Ascierto has presided as Principal Investigator on over 160 clinical trials and he is the author of more than 750 publications in peer-reviewed journals. Such journals include: The New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology, and Clinical Cancer Research, among others. Primarily, his major research interests have included research in immunotherapy and vaccination treatments of solid tumors, combination strategies with I-O, genetics and proteomics of melanoma, assessment of new molecular markers for tumor progression, biochemical and immunological monitoring.
